ArticleArchives of rheumatology2026
A Cross-Sectional Study on Elevated Serum Calcitonin Gene-Related Peptide Levels in Rheumatoid Arthritis Patients and Their Relationship with Disease Activity.
Article in Archives of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThis study aims to assess serum levels of calcitonin gene-related peptide (CGRP) in patients with rheumatoid arthritis (RA), compare these levels with those of healthy controls, and analyze their correlation with disease activity. MATERIALS AND
methodsThis cross-sectional, case-controlled study involved 80 individuals diagnosed with RA based on the American College of Rheumatology/The European Alliance of Associations for Rheumatology (ACR/EULAR) 2010 criteria and 40 healthy individuals serving as the control group. Demographic data, along with clinical and laboratory findings of the participants, were documented for analysis. C-reactive protein (CRP), CGRP, and erythrocyte sedimentation rate (ESR) levels were measured in both the RA and control groups. Disease activity among patients with RA was assessed using the Visual Analog Scale (VAS), Disease Activity Score- 28 (DAS-28), and Health Assessment Questionnaire (HAQ). Logistic regression was performed to identify significant predictors, and the optimal cut-off value was established through receiver operating characteristic (ROC) analysis.
resultsThe median serum CGRP level in patients with RA (91.1 pg/mL) was significantly higher than that of the control group (40.8 pg/mL) (P < .001). The median serum CGRP level was significantly greater in seropositive patients with RA (118.7 pg/mL) compared to seronegative patients (66.1 pg/mL) (P = .017). The ROC analysis identified 61.78 pg/mL as the optimal CGRP cut-off to distinguish patients with RA from controls, with 70% sensitivity and 87.5% specificity (Area Under the Curve (AUC): 0.839, P < .001). A significant correlation was observed between CGRP levels in patients with RA and the scores of DAS-28, HAQ, VAS-Patient, and VASPhysician (P = .001, P = .006, P < .001, P = .001). Logistic regression analyses demonstrated that increases in CGRP (P = .002) and CRP (P = .011), as well as CGRP (P = .001) and ESR (P < .001), were each significantly associated with higher odds of active disease.
conclusionThe findings suggest that higher serum CGRP levels may contribute to the pathophysiology of RA, potentially indicating disease progression, joint damage, and supporting prognosis in the management of RA. Cite this article as: Dede Akpınar M, Ataoğlu S, Cangür Ş. A crosssectional study on elevated serum calcitonin gene-related peptide levels in rheumatoid arthritis patients and their relationship with disease activity. ArchRheumatol. 2026;41(1):29-39.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.